Tobii prepares to spin off Tobii Dynavox
STOCKHOLM, April 29, 2021 /PRNewswire/
The Board of Directors of Tobii today announced that it is conducting a review of the group s structure and has initiated work intended to prepare for a public listing of Tobii Dynavox, following distribution of its shares to the shareholders of Tobii, in accordance with the rules of Lex Asea[1].
Tobii s Board of Directors believes that a split of Tobii Group into two parts - one consisting of the division Tobii Dynavox and the other of a merge of the two divisions Tobii Pro and Tobii Tech - has the potential to further accelerate the long-term business growth and success of both entities, and hence create substantial shareholder value.
Share this article
STOCKHOLM, Jan. 29, 2021 /PRNewswire/
On November 16, 2020, OncoZenge AB (publ), Moberg Pharma s subsidiary, announced that the company had secured financing of a total of approximately SEK 70 million ahead of the spin-off and separate listing on Nasdaq First North Growth Market. Today, the Board of Moberg Pharma has decided that the record date for the right to receive shares in OncoZenge shall be February 5, 2021. The Board of OncoZenge has today, with the support of an authorization from an Extraordinary General Meeting on January 21, 2021, decided on the terms for the rights issue of approximately SEK 60 million (the Rights Issue ). In addition, an indicative timetable for both the Rights Issue and the listing process on Nasdaq First North Growth Market is announced, where the first day of trading is expected to be on February 12, 2021.
Moberg Pharma announces the last day of trading in BTU and the first trading day in warrants Moberg Pharma AB (publ)’s (OMX: MOB) (“Moberg Pharma” or the “Company”) rights issue of units of approximately MSEK 150 (the “Rights Issue”) has now been registered with the Swe.